Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Prosper Benhaim

Hand Surgery Los Angeles, CA Medical Doctor

NPI 1669558615 CMS profile 75099

10833 Le Conte Ave, Los Angeles, CA 90095

Open in the dashboard

General payments

$492,193

324 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Prosper Benhaim of Los Angeles, CA is reported in the CMS Open Payments database as having received $492,193 across 324 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Hand Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $94,008 38
2024 General $96,124 58
2023 General $87,706 72
2022 General $52,130 38
2021 General $55,238 29
2020 General $25,364 11
2019 General $81,622 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Prosper Benhaim
  • Hand Surgery median
  • Middle half of Hand Surgery
  • National median

In program year 2025, general payments to Prosper Benhaim were reported at $94,008. Among 1,842 Hand Surgery profiles paid that year, the median was $270 and the middle half received between $102 and $1,118.

Show as a table
Year Prosper Benhaim Hand Surgery median Middle half National median
2019 $81,622 $383 $106–$1,905 $163
2020 $25,364 $172 $51–$1,268 $114
2021 $55,238 $263 $71–$1,591 $132
2022 $52,130 $336 $87–$1,938 $149
2023 $87,706 $233 $81–$1,114 $160
2024 $96,124 $258 $88–$1,203 $164
2025 $94,008 $270 $102–$1,118 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Endo Pharmaceuticals Inc. $299,855 225 payments
  2. Endo USA, Inc. $134,750 56 payments
  3. AxoGen $36,355 31 payments
  4. Medartis Inc. $19,436 2 payments
  5. Micromed Inc $1,171 2 payments
  6. TriMed, Inc. $290 4 payments
  7. TELA Bio, Inc. $140 1 payment
  8. Zimmer Biomet Holdings, Inc. $117 1 payment
  9. Ossur Americas., Inc $57 1 payment
  10. Integra LifeSciences Corporation $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $318,360 67 payments
  2. Consulting Fee $132,080 23 payments
  3. Travel and Lodging $27,578 111 payments
  4. Food and Beverage $10,745 119 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $2,125 1 payment
  6. Education $1,304 3 payments
Products named General payments · program years 2019–2025
  1. XIAFLEX $434,605 281 payments
  2. Avance Nerve Graft $20,471 21 payments
  3. APTUS $19,436 2 payments
  4. AXOGUARD NERVE PROTECTOR $18,710 15 payments
  5. AxoGuard Nerve Connector $18,710 15 payments
  6. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $140 1 payment
  7. Biomet Orthopak $117 1 payment
  8. Tools - WFS $98 2 payments
  9. AXOGUARD NERVE CAP $92 1 payment
  10. Axoguard HA+ Nerve Protector $92 1 payment
  11. Other $78 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

101

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$630

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

0%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 37 $247
Methylprednisolone Generic 23 $151
Oxycodone Hcl Generic 30 $136
Ibuprofen Generic 11 $97

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 128 billing codes

Paid by Medicare

$450,395

Of which drugs: $216,383

Medicare patients

364

Average age 73

Services billed

5,848

233 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 69%
High blood pressure 61%
Ischemic heart disease 29%
Osteoporosis 27%
Depression 26%
Diabetes 24%
Cancer 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, collagenase, clostridium histolyticum, 0.01 mg J0775 Office 33 3,960 $216,049
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 155 459 $334

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIAFLEX
  • Endo USA, Inc. $60,204
  • Endo Pharmaceuticals Inc. $35,673
$95,877 — 3,960

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hand Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record